| Name | Title | Contact Details |
|---|
Vial is a leading clinical trial site network that runs highly efficient clinical trials. Vial operates a network of clinical trial research sites within Dermatology clinics across the country. Vials clinical trial recruiting engine, software and oper...
Groups360™️ was founded in 2014 with the goal of simplifying and transforming the ways meetings are booked. The company`s search engine, GroupSync™️, using its proprietary matching algorithms designed specifically for meeting planners, has helped place thousands of events at the right venue, saving planners time and money. GroupSync`s price predictor tool delivers improved transparency, reducing time and effort required to book meetings for both the hotel and the planner. Groups360`s management team has decades of experience in the meetings and events industry and provides the right mix of technology and experienced advisors. Using GroupSync, planners can search more than 200,000 properties in 225 countries and territories.
Acuity Medical Systems is a Wayzata, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Mission Healthcare is a provider of home-based healthcare and hospice services in Southern California. They offer a wide range of professional healthcare and support services provided in the home, including home health, home care, and hospice.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic